Publications by authors named "Maria Beatrice Principi"
Background: Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBDs) with a rapidly growing worldwide incidence. The last decades presented rapid progress in pharmacological treatment leading in many cases to clinical and endoscopic remission, including biological treatment with anti-TNF agents.
Aim: The exact timing of introduction, optimization and maintenance of anti-TNF therapy in IBDs is not thoroughly covered in current guidelines.
Article Synopsis
- The study compared the effectiveness of ustekinumab and vedolizumab as second-line treatments for Crohn's disease in patients who did not respond to TNF inhibitors, with outcomes assessed through clinical measures and imaging techniques.
- Results showed no significant differences in clinical outcomes at 26 weeks, but at 52 weeks, vedolizumab performed better with higher rates of clinical remission (55.5% vs 42.5%) and steroid-free remission (51.1% vs 40.6%).
- Both treatments had similar safety profiles, and clinical responses at 26 weeks were predictive of later steroid-free remission for both medications.
Pathologists are often called upon to diagnose colitides that differ from the two main forms of inflammatory bowel disease (IBD). These non-IBD colitides include infectious colitis, microscopic colitis, ischemic colitis, eosinophilic colitis, autoimmune enterocolitis, segmental colitis associated with diverticulosis, drug-induced colitis, radiation colitis and diversion colitis. The diagnosis of these different disease entities relies on the histopathological examination of endoscopic biopsies of the gastrointestinal tract.
View Article and Find Full Text PDFBackground: Golimumab is a new anti-TNF-alpha monoclonal antibody for patients with ulcerative colitis.
Aims: To assess the short- and long-term effectiveness and safety of golimumab in daily clinical practice and to identify predictors of response.
Methods: Consecutive patients treated with golimumab in 22 Italian centers were enrolled.
Aim: To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs.
Methods: All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected.
Epidemiological and experimental studies suggest a protective role of estrogens against colorectal cancer. This effect seems to be mediated by their binding to estrogen receptor beta (ER-beta), one of the two estrogen receptors with high affinity for these hormones. Very recently, the demonstration of an involvement of ER-beta in the development of adenomatous polyps of the colon has also been documented, suggesting the use of selective ER-beta agonists in primary colorectal cancer prevention.
View Article and Find Full Text PDF